In vitro effect of anti-human immunodeficiency virus CCR5 antagonist maraviroc on chemotactic activity of monocytes, macrophages and dendritic cells

Clinical and Experimental Immunology

Volumn 166, Issue 2, 2011, Pages 184-190

  Rossi, R ^a   Lichtner, M ^a,b   de Rosa, A ^a   Sauzullo, I ^a   Mengoni, F ^a   Massetti, A P ^a   Mastroianni, C M ^a,b   Vullo, V ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

CCR5; Chemotaxis; Dendritic cells; HIV; Maraviroc

Indexed keywords

CD14 ANTIGEN; CHEMOATTRACTANT; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOTACTIC FACTOR; FORMYLMETHIONYLLEUCYLPHENYLALANINE; FORMYLPEPTIDE RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MARAVIROC; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; T6 ANTIGEN;

ARTICLE; CELL MIGRATION; CELL SECRETION; CHEMOTAXIS; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INNATE IMMUNITY; LYMPHOCYTE RECIRCULATION; MACROPHAGE; MONOCYTE; NERVE CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

CHEMOKINE CCL2; CHEMOKINE CCL4; CHEMOKINE CCL5; CHEMOTAXIS; CHEMOTAXIS, LEUKOCYTE; CYCLOHEXANES; DENDRITIC CELLS; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; MACROPHAGES; MONOCYTES; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; RECEPTORS, CCR5; TRIAZOLES;

EID: 80053644416     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04409.x     Document Type: Article

References (31)

1. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000; 343:338-44.
2. Luster AD. The role of chemokines in linking innate and adaptive immune response. Curr Opin Immunol 2002; 14:129-35.
3. Lederman MM, Nicholson AP, Cho M etal. Biology and CCR5 and its role in HIV infection and treatment. JAMA 2006; 296:815-26.
4. Deng H, Liu R, Ellmeier W etal. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
5. Dragic T, Litwin V, Allaway GP etal. HIV-1 entry into CD41 cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
6. MacArthur RD, Novak RM. Maraviroc: the first of a new class of antiretroviral agents. Clin Infect Dis 2008; 47:236-41.
7. Soriano V, Geretti AM, Perno CF etal. Optimal use for maraviroc in clinical practice. AIDS 2008; 22:2231-40.
8. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30:1228-50.
9. Emmelkamp JM, Rockstroh JK. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions - review of the literature. Eur J Med Res 2007; 12:409-17.
10. Soriano V, Perno CF, Kaiser R etal. When and how to use maraviroc in HIV-infected patients. AIDS 2009; 23:2377-885.
11. Corbeau P, Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. AIDS 2009; 23:1931-43.
12. Alkhatib G. The biology of CCR5 and CXCR4. Curr Opin HIV AIDS 2009; 4:96-103.
13. Rossi R, Lichtner M, Sauzullo I etal. Downregulation of leukocyte migration after treatment with CCR5 antagonist maraviroc. J Acquir Immune Defic Syndr 2010; 54:e13-14.
14. Ahuja SK, Gao JL, Murphy PM. Chemokine receptors and molecular mimicry. Immunol Today 1994; 15:281-7.
15. Yang D, Chen Q, Le Y etal. Differential regulation of formyl peptide receptor-like 1 expression during the differentiation of monocytes to dendritic cells and macrophages. J Immunol 2001; 166:4092-8.
16. Shen W, Li B, Wetzel MA etal. Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes. Blood 2000; 96:2887-94.
17. Le Y, Wetzel MA, Shen W etal. Desensitization of chemokine receptor CCR5 in dendritic cells at the early stage of differentiation by activation of formyl peptide receptors. Clin Immunol 2001; 99:365-72.
18. Dhillon NK, Williams R, Callen S, Zien C, Narayan O, Buch S. Roles of MCP-1 in development of HIV-dementia. Front Biosci 2008; 13:3913-18.
19. El-Asmar L, Springael JY, Ballet S, Andrieu EU, Vassart G, Parmentier M. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol Pharmacol 2005; 67:460-9.
20. Jones GJ, Watera C, Patterson S. Comparative loss and maturation of peripheral blood dendritic cell subpopulations in African and non-African HIV-1-infected patients. AIDS 2001; 15:1657-63.
21. Coleman CM, Wu L. HIV interactions with monocytes and dendritic cells: viral latency and reservoirs. Retrovirology 2009; 6:143-54.
22. Marin B, Thiébaut R, Bucher HC etal. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-53.
23. Soehnlein O, Weber C. Myeloid cells in atherosclerosis: initiators and decision shapers. Semin Immunopathol 2009; 31:35-47.
24. Lichtner M, Cuomo MR, Rossi R etal. Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment. Atherosclerosis 2009; 204:e1-3.
25. Pacanowski J, Kahi S, Baillet M etal. Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001; 98:3016-21.
26. Lichtner M, Rossi R, Rizza MC etal. Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count. Curr HIV Res 2008; 6:19-27.
27. Hardy AW, Graham DR, Shearer GM etal. HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc Natl Acad Sci USA 2007; 104:17453-8.
28. Lichtner M, Marañón C, Vidalain PO etal. HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res Hum Retroviruses 2004; 20:175-82.
29. Gong X, Feng H, Zhang S etal. Increased expression of CCR5 in experimental autoimmune myocarditis and reduced severity induced by anti-CCR5 monoclonal antibody. J Mol Cell Cardiol 2007; 42:781-91.
30. Lim JK, Louie CY, Glaser C etal. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-5.
31. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009; 4:131-5.